VBI Vaccines Inc. (VBIV) Sets 1-Year Low at $2.63

June 29, 2018 - By Joshua Cleveland

VBI Vaccines Inc. (NASDAQ:VBIV) Corporate Logo

VBI Vaccines Inc. (NASDAQ:VBIV) broke into one-year low with $2.42 price target or 8.00 % below the last $2.63 price per share. The one-year low was reported on Jun, 29 by Barchart.com. It has $168.89M market cap. At $2.42 price target, the company’s valuation could be $13.51M less.

VBIV hit $2.63 during the last trading session after $0.13 change.Currently VBI Vaccines Inc. is downtrending after 26.86% change in last June 29, 2017. VBIV has also 68,106 shares volume. VBIV underperformed by 39.43% the S&P 500.

There’s a significant VBI Vaccines Inc. (NASDAQ:VBIV) news released by Nasdaq.com. It’s a report titled: “VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference” on June 19, 2018.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally.The firm is valued at $168.89 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process.Currently it has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.